Nektar initiates Phase 2b clinical study of alopecia areata candidate

Nektar initiated its Phase 2b clinical trial evaluating rezpegaldesleukin in patients with severe to very severe alopecia areata. Rezpegaldesleukin is a novel agonistic T regulatory cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immune balance by directly expanding functional T reg cells and engaging multiple immunoregulatory pathways. Nektar expects topline data from this study expected in the first half of 2025. Initial results from the study are anticipated in the first half of 2025.